Tag Archives: Glaukos

Ivantis Fires Back: It Petitions for Invalidation of the Glaukos iStent® Patent

Last month, it was reported that Glaukos filed a lawsuit against Ivantis, alleging that the Ivantis Hydrus Microstent device infringes on patents held by Glaukos covering its iStent® devices. See “Glaukos Sues Ivantis over patents on iStent® Devices”.

Ivantis has now launched a response: In a filing on May 23, 2018, Ivantis has petitioned the USPTO to invalidate one of the two patents asserted by Glaukos in its lawsuit. Continue reading

Glaukos Sues Ivantis over patents on iStent® Devices

April 17, 2018: Glaukos Corporation of San Clemente, CA, has filed a patent infringement lawsuit against Ivantis, Inc. of Irvine, CA. The lawsuit was filed April 14, 2018.

The patents involved are:
U.S. Patent No. 6,626,858 (Lynch et al.), “Shunt Device and Method For Treating Glaucoma”
U.S. Patent No. 9,827,143 (Lynch et al.), “Shunt Device and Method For Treating Ocular Disorders”

In its Complaint, Glaukos alleges that the Ivantis Hydrus Microstent device infringes on patents held by Glaukos covering its iStent® devices.
Continue reading

Glaukos obtains patent: “Shunt device and method for treating ocular disorders”

November 28, 2017: Glaukos Corporation of San Clemente, CA, obtained U.S. Patent No. 9,827,143, “Shunt device and method for treating ocular disorders”.

According to the abstract of the patent:

Shunt devices and a method for continuously decompressing elevated intraocular pressure in eyes affected by glaucoma by diverting excess aqueous humor from the anterior chamber of the eye into Schlemm’s canal where post-operative patency can be maintained with an indwelling shunt device which surgically connects the canal with the anterior chamber. The shunt devices provide uni- or bi-directional flow of aqueous humor into Schlemm’s canal.

Claim 1 of the issued patent recites:

1. An ocular implant configured to maintain patency of Schlemm’s canal in a stenting fashion, the ocular implant comprising: a body of biocompatible material of a size and shape adapted to be at least partially circumferentially retained within a portion of Schlemm’s canal, wherein the body is non-tubular, wherein the body is curved, and wherein the body comprises at least one opening along its length configured to facilitate passage of aqueous humor.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09827143.

Glaukos: Application published: “Systems and Methods for Delivering an Ocular Implant to the Suprachoroidal Space within an Eye”

November 2, 2017: The USPTO today published a patent application filed by Glaukos Corporation of San Clemente, CA: U.S. Application Publication No. 2017/0312124, “Systems and Methods for Delivering an Ocular Implant to the Suprachoroidal Space within an Eye”.

According to the published abstract:

Delivery devices, systems and methods are provided for inserting an implant into an eye. The delivery or inserter devices or systems can be used to dispose or implant an ocular stent or implant, such as a shunt, in communication with the suprachoroidal space, uveal scleral outflow pathway, uveoscleral outflow path or supraciliary space of the eye. The implant can drain fluid from an anterior chamber of the eye to a physiologic outflow path of the eye, such as, the suprachoroidal space, uveal scleral outflow pathway, uveoscleral outflow path or supraciliary space. Alternatively, or in addition, the implant can elute a drug or therapeutic agent. The delivery or inserter devices or systems can be used in conjunction with other ocular surgery, for example, but not limited to, cataract surgery through a preformed corneal incision, or independently with the inserter configured to make a corneal incision. The implant can be preloaded with or within the inserter to advantageously provide a sterile package for use by the surgeon, doctor or operator.

The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20170312124.

Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is simply a copy of the as-filed application, without examination.

Glaukos obtains patent: “Intraocular physiological sensor”

August 15, 2017: Glaukos Corporation of San Clemente, CA, obtained U.S. Patent No. 9,730,638, “Intraocular physiological sensor”.

According to the abstract of the patent:

An implantable intraocular physiological sensor for measuring a physiological characteristic, such as intraocular pressure. The implantable intraocular physiological sensor may include a tubular main body configured to house one or more electrical components. The implantable intraocular physiological sensor may also include a sensor cap configured to be inserted into a first end of the tubular main body with a moisture barrier seal. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09730638.

Glaukos: Application published: “Shunt Device and Method for Treating Ocular Disorders”

August 3, 2017: The USPTO today published a patent application filed by Glaukos Corporation of San Clemente, CA: U.S. Application Publication No. 2017/0216095, “Shunt Device and Method for Treating Ocular Disorders”.

According to the published abstract:

Shunt devices and a method for continuously decompressing elevated intraocular pressure in eyes affected by glaucoma by diverting excess aqueous humor from the anterior chamber of the eye into Schlemm’s canal where post-operative patency can be maintained with an indwelling shunt device which surgically connects the canal with the anterior chamber. The shunt devices provide uni- or bi-directional flow of aqueous humor into Schlemm’s canal.

The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20170216095.

Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is simply a copy of the as-filed application, without examination.

Dose Medical obtains patent: “Implants with controlled drug delivery features and methods of using same”

March 28, 2017: Dose Medical Corporation of Laguna Hills, CA, an affiliate of Glaukos Corporation, obtained U.S. Patent No. 9,603,738, “Implants with controlled drug delivery features and methods of using same”.

According to the abstract of the patent:

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more, drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09603738.

Glaukos obtains patent: “Devices and methods for glaucoma treatment”

March 21, 2017: Glaukos Corporation of San Clemente, CA, obtained U.S. Patent No. 9,597,230, “Devices and methods for glaucoma treatment”.

According to the abstract of the patent:

Intraocular implants and delivery instruments are disclosed for treating ophthalmic conditions and ocular disorders, such as glaucoma. The implants are configured to extend between the anterior chamber of the eye and a fluid outflow path or physiologic outflow pathway, such as Schlemm’s canal, of the eye for enhancing outflow of aqueous from the anterior chamber so as to reduce intraocular pressure. The implants can have features for anchoring the implant into the physiologic outflow pathway as well as preventing the walls of the physiologic outflow pathway from closing the outlet of the implants. The delivery instruments can be steerable so as to make implantation easier. Additionally, the delivery instruments can be configured to hold a plurality of implants so that multiple implants can be implanted through one incision without removing the delivery instrument from the incision between serial implantations.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09597230.

Glaukos obtains patent: “Systems and Methods for Delivering an Ocular Implant to the Suprachoroidal Space within an Eye”

March 14, 2017: Glaukos Corporation of San Clemente, CA, obtained U.S. Patent No. 9,592,151, “Systems and Methods for Delivering an Ocular Implant to the Suprachoroidal Space within an Eye”.

According to the abstract of the patent:

Delivery devices, systems and methods are provided for inserting an implant into an eye. The delivery or inserter devices or systems can be used to dispose or implant an ocular stent or implant, such as a shunt, in communication with the suprachoroidal space, uveal scleral outflow pathway, uveoscleral outflow path or supraciliary space of the eye. The implant can drain fluid from an anterior chamber of the eye to a physiologic outflow path of the eye, such as, the suprachoroidal space, uveal scleral outflow pathway, uveoscleral outflow path or supraciliary space. Alternatively, or in addition, the implant can elute a drug or therapeutic agent. The delivery or inserter devices or systems can be used in conjunction with other ocular surgery, for example, but not limited to, cataract surgery through a preformed corneal incision, or independently with the inserter configured to make a corneal incision. The implant can be preloaded with or within the inserter to advantageously provide a sterile package for use by the surgeon, doctor or operator.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09592151.

Glaukos Corporation obtains patent: “Implant delivery system and methods thereof for treating ocular disorders”

February 21, 2017: Glaukos Corporation of San Clemente, CA, obtained U.S. Patent No. 9,561,131, “Implant delivery system and methods thereof for treating ocular disorders”.

According to the abstract of the patent:

Surgical methods and related medical devices for treating glaucoma are disclosed. The method comprises trabecular bypass surgery, which involves bypassing diseased trabecular meshwork with the use of a stent implant. The stent implant is inserted into an opening created in the trabecular meshwork by a piercing member that is slidably advanceable through the lumen of the stent implant for supporting the implant insertion. The stent implant is positioned through the trabecular meshwork so that an inlet end of the stent implant is exposed to the anterior chamber of the eye and an outlet end is positioned into fluid collection channels at about an exterior surface of the trabecular meshwork or up to the level of aqueous veins.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09561131.